BioCote, the antimicrobial solutions provider, has demonstrated that its antimicrobial technology can eliminate over 99.9% of carbapenem-resistant Klebsiella pneumoniae (CRKP). Carbapenem-resistant Enterobacteriaceae (CRE) is a family of bacteria that, over the past decade, have caused increasing problems in healthcare environments. Most commonly, CRE-related infections occur among individuals who are hospitalised, critically ill or who require invasive devices such as ventilators as part of their healthcare. They are dangerous because they are resistant to the carbapenem antibiotics, which are recognised as being among the most powerful antibiotics available.
www.biocote.com
